Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19
pandemic that has resulted in more than one million infections and 73,000 deaths,. Vaccine …

Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …

Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …

The highly mutated SARS-CoV-2 Omicron (B. 1.1. 529) variant has been shown to evade a
substantial fraction of neutralizing antibody responses elicited by current vaccines that …